Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Alder on the establishment of Alder III
Mandate

Vinge has advised Alder on the establishment of Alder III

May 27, 2024 Private Funds

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.

Alder has successfully raised approximately SEK 3.1bn in investment commitments from an international investor base, doubling the total investor commitments as compared to its predecessor fund Alder II.

Alder closed its first fund in 2010 and focuses on investing in sustainable technology companies with profitable growth and a turnover of between SEK 100 and 750 million. Alder primarily invests as a majority shareholder in companies established in the Nordic region but may also invest selectively in the rest of Europe. Alder's funds - including Alder III - are classified as so-called Article 9 funds under the SFDR.

Vinge's team primarily consisted of Johan Larsson, Mattias Schömer, Martin Cronsioe, Viveka Classon, Nils Unckel, Ulf Nilsson, Emelie Svanberg, Anton Sjökvist, Semir Omerbasic, Tobias Onegård Karlsson, Marcus Andersson, Viktoria Wnuk, Emelie Zingmark, Helena Göransson,Kamyar Najmi and Nour Makie.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025